RxDoctor Payments Data

Elizabeth Clayton, DO

Hospitalist · Baltimore, MDNPI 1194167734

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Lilly USA, LLC at 24.4% of the total. Reporting peaked in 2023 at $339 and has fallen 88.9% since, to $38 in 2025.

$549in general payments, 2019–2025

Across 15 payments — averaging $36.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$134
  • AstraZeneca$90
  • Eli Lilly$83
  • Mallinckrodt Hospital Products Inc.$59
  • E.r. Squibb & Sons, L.L.C.$54
  • Mallinckrodt Enterprises LLC$36
  • plus $93 from 4 others

What the payments were for

  • Food & beverage$549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$549 in reported general payments places this provider in the 85th percentile of 414 hospitalist providers in Maryland.

See all hospitalist providers in Maryland

Medicare billing

Part B allowed, 2024
$32,097
Medicare patients
238
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan20$11,018
Atorvastatin Calcium30$557
Metoprolol Succinate16$367
Omeprazole13$366
Hydralazine Hcl18$313
Levothyroxine Sodium29$305
Potassium Chloride14$285
Trazodone Hcl27$273
Allopurinol16$248
Hydrochlorothiazide23$153
Quetiapine Fumarate20$92
Amlodipine Besylate18$73
Furosemide15$47
Prednisone11$28

Paid to pharmacies, not to this prescriber.

Other hospitalist in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →